Bharat Serums and Vaccines Limited (BSV), a Mankind Group Company, is ramping up its initiatives to tackle the rising incidence of snakebites across India, particularly with the onset of the monsoon season. With a strong focus on the 4A’s—Awareness, Accessibility, Availability, and Action—BSV is committed to ensuring timely and effective snakebite treatment is accessible nationwide.
Sivani Sarma Deka, COO of India Business at BSV, highlighted, “We take our leadership role seriously and are working tirelessly to enhance awareness, improve access, and ensure the availability of antivenom across rural and urban areas. Our focus is on timely intervention and educating communities to reduce myths surrounding snakebite management.” BSV’s efforts include forging multi-sectoral collaborations and providing continuous medical education for healthcare providers on best practices for managing snakebite envenomation.
The government’s recent decision to declare snakebites a “notifiable disease” is expected to drive better surveillance, resource allocation, and quicker interventions across the country.
